In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.
Last year and as previously communicated, Navinci took important steps towards accelerating commercialization and market leadership in spatial proteomics. In July, Navinci announced the closing of a SEK 90 million financing led by Segulah Medical Acceleration together with the existing shareholders. In September, the company launched the first commercial assay to accurately detect and visualize the immune checkpoint interaction between the programmed cell death protein 1 (PD1) and PD1-ligand (PD-L1) in tissue samples. The assay launch is the first step in building a complete portfolio of target-specific assays for immune-oncology research and represents a significant advance in spatial proteomics. Rounding out 2022, Navinci released a first of its kind proximity ligation assay, the Naveni TriFlex Cell. The TriFlex assay simultaneously detects individual proteins and their interaction thereby providing a powerful tool to study proteins and their interplay in cells.
In line with the growing focus on commercialization, the company appointed Dr Eva Pisa as new chairman of the board. Dr. Pisa started her career at Karolinska Institute in Stockholm and has 30 years of experience from R&D and commercial roles in diagnostic and life science industries. Dr. Pisa currently serves on the Board of Directors of HSE AG, Switzerland, Envetec Ltd., Ireland and Qiagen NV, Holland. Maria Tell also joins the Board representing Segulah Medical Acceleration. Ms. Tell brings over 15 years of experience in marketing, business strategy, investment, and investor relations within the life science and medtech industries. Navinci also established a Scientific Advisory Board chaired by founder and co-owner, Professor Ulf Landegren. The Scientific Advisory Board members are Professor Jan Anderson, Karolinska Institute, Professor Mats Nilsson, Stockholm University, Professor Carolina Wählby, Uppsala University and Assistant Professor Daniel Fürth, Uppsala University. The group comprises of individuals with deep expertise in the fields of image analysis, in situ technology development and medical research.
The Navinci leadership team, led by CEO Robert Gunnarsson, is strengthened with the recruitment of Dr. Caroline Gallant, taking on a newly formed role as Chief Technology Officer. Dr Gallant joins Navinci from 10X Genomics and brings extensive experience of in situ molecular technology development. Dr. Gallant will lead the companies technology innovation activities, whereas Dr. Agata Zieba Wicher, Chief Scientific Officer, will lead the product development and scientific collaborations. As will be announced shortly, Navinci has recruited a new Chief Business Officer who will lead the organizational build-up and commercialization of the unique Navinci product portfolio.
“I am excited to join Navinci in this dynamic and fast-moving phase. Navinci has an exciting product offering based on unique technology invented by Ulf Landegren and colleagues. The talented team has delivered on the set strategy and goals and created an offer that differentiates Navinci from other actors in the field. I am looking forward to working with the board of directors and the Navinci team to contribute to increased understanding of the fascinating world of protein interactions.”. – Eva Pisa, Chairman of the Board.
“I am looking forward to working with Eva Pisa on the next exciting part of Navinci´s journey in providing tools to better understand the protein interactions in immune oncology. With the addition of Caroline Gallant to the leadership team and her expertise in this field we have further strengthened our scientific power. I am also pleased that we could attract such outstanding scientific professionals to our Scientific Advisory Board who will provide us with cutting edge knowledge in imaging techniques, molecular tools and bring clinical oncology insights.” – Robert Gunnarsson, CEO of Navinci Diagnostics AB.
Recommended articles
